Welcome!

News Feed Item

US Excipients Market



 

 

 

LONDON, Aug. 5, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:



US Excipients Market

http://www.reportbuyer.com/pharma_healthcare/general_industry/us_excipients_market.html


US demand to grow 4.3% annually through 2018

Demand for pharmaceutical excipients in the US is projected to rise 4.3 percent per year to $2.0 billion in 2018. In volume terms, demand is expected to grow 1.9 percent annually to 900 million pounds over the same period. While continued growth in pharmaceutical output will be the primary driver of increases in excipient demand, gains will accelerate as excipients play a larger role in bringing additional value to pharmaceutical products by improving properties such as the controlled release or improved
absorption of active ingredients.


Preservatives, suspension agents to see strong gains

Trends in pharmaceutical output by dosage formulation will have a strong influence on excipient demand by application. Output of parenteral preparations is expected to rise at an especially strong pace through 2018, supporting demand for suspension agents and preservatives. Solvents are also projected to benefit from increased shipments of parenteral drugs, although gains in dollar terms will be limited by the continued decline in glycerin prices due to oversupply.
Oral preparations are the largest category of pharmaceutical dosage formulations; thus, oral pharmaceuticals tend to require more excipients than other types of drugs and have a significant impact on excipient demand. Shipments of oral pharmaceuticals are forecast to rise at a faster pace than seen in the 2008-2013 period, supporting accelerated gains in demand for fillers, binders, coatings, flavoring agents, capsules, and disintegrants. In addition, oral formulations such as delayed- and extended-release tablets and capsules and dissolving tablets are expected to boost their market share, further raising demand for excipients such as binders and disintegrants.


Specialty excipient blends to add value to product mix

A major development in the excipient and pharmaceutical industries is the increased dependence on specialty excipient blends. Specialty excipient blends can add value to pharmaceutical products by differentiating them from competitive products, and by optimizing the production process. These value-added excipient blends are often formulated for usage in specific manufacturing processes such as direct compression or wet granulation, and are optimized for certain performance characteristics such as delayed- or extended-release oral tablets. Product differentiation will play an increasingly important role going forward as generic pharmaceutical products increase their market share and as consumers take a more active role in choosing their drugs from among a wide range of products with the same active pharmaceutical ingredients.


Polymers to benefit from specialty blend advances

Product versatility will be a key factor impacting product mix in excipient demand going forward, especially as specialty excipient blends play an increasingly important role in pharmaceutical formulation. Polymers -- including cellulose derivatives, povidone, starch, polyethylene glycol, acrylic polymers, and natural gums -- are expected to benefit from this trend as many of these products can function in multiple applications and are easily formulated with other excipients. These favorable characteristics will serve to offset the higher prices associated with some polymers.


Study coverage

Excipients, an upcoming industry study presents historical demand data (2003, 2008, 013) plus forecasts for 2018 and 2023 by product type and application. This study also analyzes market environment factors, evaluates company market share and profiles 47 US industry competitors.
INTRODUCTION x
I. EXECUTIVE SUMMARY 1
II. MARKET ENVIRONMENT 4
General 4
Economic Factors 5
Demographic Patterns 9
Health Care Trends 13
National Health Expenditures 14
Medical Conditions 17
Chronic Conditions 18
Acute Conditions 20
Pharmaceuticals 22
Therapeutic Class 23
Dosage Formulations 24
Distribution Classifications 26
Commercial Status 28
Regulatory Overview 29
Historical Market Trends 31
Pricing Trends 32
Foreign Trade 34
International Markets 35
III. PRODUCTS 37
General 37
Polymers 43
Cellulose Derivatives 46
Microcrystalline Cellulose (MCC) 47
Hydroxypropyl Methylcellulose (HPMC) 50
Ethyl Cellulose 54
Methyl Cellulose 55
Carboxymethylcellulose (CMC) 57
Croscarmellose Sodium 59
Other Cellulose Excipients 61
Povidone 64
Starch Compounds 67
Pregelatinized Starch 69
Sodium Starch Glycolate 71
Other Starch Excipients 73
Polyethylene Glycol 77
Acrylic Polymers 80
Other Polymers 84
Natural Gums from Seaweeds 85
Other Natural Gums 88
All Other Polymers 90
Alcohols 91
Propylene Glycol 93
Glycerin 94
Sorbitol 96
Other Alcohols 98
Mannitol 99
Other Polyol Excipients 100
All Other Alcohols 104
Minerals 104
Calcium Phosphate 107
Calcium Carbonate 109
Clay 110
Mineral Hydrocarbons 112
Silicon Dioxide 115
Titanium Dioxide 117
Other Minerals 118
Gelatin 121
Sugars 125
Lactose 127
Sucrose 129
Other Sugar Excipients 131
Other Pharmaceutical Excipients 134
Dyes & Pigments 137
Flavors 138
Surfactants 139
Acidulants 142
Antioxidants & Antimicrobials 143
All Other Compounds 145
Stearate Compounds 145
Electrolytes & Related Compounds 146
Chemical Plasticizers 146
High Intensity Sweeteners 147
Natural Fats & Oils 149
Natural Waxes 150
IV. APPLICATIONS 152
General 152
Fillers & Diluents 155
Binders 157
Suspension & Viscosity Agents 160
Coatings 162
Solvents 164
Flavoring Agents 166
Capsules 168
Disintegrants 171
Colorants 173
Lubricants & Glidants 174
Preservatives 176
Other Applications 177
V. INDUSTRY STRUCTURE 179
General 179
Market Share 181
Competitive Strategies 184
Industry Restructuring 185
Cooperative Agreements 187
Marketing & Distribution 191
Research & Development 192
Manufacturing 193
Company Profiles 194
ABITEC, see Associated British Foods
Akzo Nobel NV 195
ANGUS Chemical, see Dow Chemical
Archer-Daniels-Midland Company 196
Ashland Incorporated 198
Associated British Foods plc 201
Avantor Performance Materials Incorporated 204
BASF SE 206
Berkshire Hathaway Incorporated 209
Berwind Corporation 211
Cabot Corporation 213
Cargill Incorporated 215
Celanese Corporation 218
Colorcon, see Berwind
Corn Products International, see Ingredion
CP Kelco US, see Huber (JM)
Croda International plc 220
CyDex Pharmaceuticals, see Ligand Pharmaceuticals
Dow Chemical Company 222
DuPont (EI) de Nemours 227
Eastman Chemical Company 229
EMD Millipore, see Merck
Evonik Industries AG 231
Ferro Corporation 234
FibroGen Incorporated 235
FLAVORx Incorporated 236
FMC Corporation 237
GELITA AG 239
Generichem Corporation 240
Huber (JM) Corporation 241
Huntsman Corporation 244
Ingredion Incorporated 245
Innophos Holdings Incorporated 247
JRS Pharma, see Rettenmaier (J.) & Söhne
Kraft Foods Group Incorporated 248
Kuraray Company Limited 249
Ligand Pharmaceuticals Incorporated 250
Lubrizol, see Berkshire Hathaway
LyondellBasell Industries NV 252
Merck KGaA 253
Mutchler Incorporated 255
Nitta Gelatin Incorporated 256
NutraSweet Company 257
Nutrinova, see Celanese
P&G Chemicals, see Procter & Gamble
PB Gelatins, see Tessenderlo Group
Pfanstiehl Incorporated 258
Procter & Gamble Company 259
Rettenmaier (J.) & Söhne GmbH & Company KG 260
Roquette Frères SA 262
Royal Dutch Shell plc 265
Sasol Limited 266
Shin-Etsu Chemical Company Limited 268
Solvay SA 270
SPI Pharma, see Associated British Foods
Stepan Company 271
Tate & Lyle plc 273
Tessenderlo Group NV 275
USG Corporation 276
Wacker Chemie AG 277
Other Companies Mentioned in Study 280


LIST OF TABLES

SECTION I -- EXECUTIVE SUMMARY
Summary Table 3
SECTION II -- MARKET ENVIRONMENT
1 Macroeconomic Indicators 9
2 Population & Households 13
3 National Health Expenditures 17
4 Chronic Conditions by Type 20
5 Acute Conditions by Type 21
6 Pharmaceutical Supply & Demand 22
7 Pharmaceutical Shipments by Therapeutic Class 24
8 Pharmaceutical Shipments by Dosage Formulation 26
9 Pharmaceutical Shipments by Distribution Classification 28
10 Pharmaceutical Shipments by Commercial Status 29
11 Excipient Market, 2003-2013 32
12 Pharmaceutical Excipient Pricing 34
SECTION III -- PRODUCTS
1 Pharmaceutical Excipient Demand by Product Group 41
2 Polymer Excipient Demand by Type & Application 44
3 Cellulose Excipient Demand by Type & Application 47
4 Microcrystalline Cellulose Excipient Demand by Application 50
5 Hydroxypropyl Methylcellulose Excipient Demand
by Application 53
6 Ethyl Cellulose Excipient Demand by Application 55
7 Methyl Cellulose Excipient Demand by Application 57
8 Carboxymethylcellulose Excipient Demand by Application 59
9 Croscarmellose Sodium Excipient Demand 61
10 Other Cellulose Excipient Demand by Application 64
11 Povidone Excipient Demand by Application 67
12 Starch Excipient Demand by Type & Application 69
13 Pregelatinized Starch Excipient Demand by Application 71
14 Sodium Starch Glycolate Excipient Demand 73
15 Other Starch Excipient Demand by Application 74
16 Polyethylene Glycol Excipient Demand by Application 80
17 Acrylic Polymer Excipient Demand by Application 84
18 Other Polymer Excipient Demand by Type & Application 85
19 Alcohol Excipient Demand by Type & Application 92
20 Propylene Glycol Excipient Demand by Application 94
21 Glycerin Excipient Demand by Application 96
22 Sorbitol Excipient Demand by Application 98
23 Other Alcohol Excipient Demand by Type & Application 99
24 Mineral Excipient Demand by Type & Application 106
25 Calcium Phosphate Excipient Demand 108
26 Calcium Carbonate Excipient Demand 110
27 Clay Excipient Demand by Application 112
28 Mineral Hydrocarbon Excipient Demand by Application 115
29 Silicon Dioxide Excipient Demand by Application 117
30 Titanium Dioxide Excipient Demand 118
31 Other Mineral Excipient Demand by Application 121
32 Gelatin Excipient Demand by Application 125
33 Sugar Excipient Demand by Type & Application 126
34 Lactose Excipient Demand by Application 129
35 Sucrose Excipient Demand by Application 131
36 Other Sugar Excipient Demand by Application 134
37 Other Pharmaceutical Excipient Demand by Type & Application 136
SECTION IV -- APPLICATIONS
1 Pharmaceutical Excipient Demand by Application 154
2 Filler & Diluent Excipient Demand by Type 157
3 Binder Excipient Demand by Type 160
4 Suspension & Viscosity Excipient Demand by Type 162
5 Coating Excipient Demand by Type 164
6 Solvent Excipient Demand by Type 166
7 Flavoring Agent Excipient Demand by Type 168
8 Capsule Excipient Demand by Type 171
9 Disintegrant Excipient Demand by Type 172
10 Colorant Excipient Demand by Type 174
11 Lubricant & Glidant Excipient Demand by Type 175
12 Preservative Excipient Demand by Type 177
13 Other Applications for Excipients by Type 178
1 US Excipient Sales by Company, 2013 180
2 Selected Acquisitions & Divestitures 187
3 Selected Cooperative Agreements 189


LIST OF CHARTS

SECTION III -- PRODUCTS
1 Excipient Demand by Product: Value & Volume, 2013 42
2 Polymer Excipient Demand: Value & Volume, 2013 45
SECTION IV -- APPLICATIONS
1 Pharmaceutical Excipient Demand by Application, 2013 155
SECTION V -- INDUSTRY STRUCTURE
1 US Excipient Market Share, 2013 182


Read the full report:
US Excipients Market

http://www.reportbuyer.com/pharma_healthcare/general_industry/us_excipients_market.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

 

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
My team embarked on building a data lake for our sales and marketing data to better understand customer journeys. This required building a hybrid data pipeline to connect our cloud CRM with the new Hadoop Data Lake. One challenge is that IT was not in a position to provide support until we proved value and marketing did not have the experience, so we embarked on the journey ourselves within the product marketing team for our line of business within Progress. In his session at @BigDataExpo, Sum...
The modern software development landscape consists of best practices and tools that allow teams to deliver software in a near-continuous manner. By adopting a culture of automation, measurement and sharing, the time to ship code has been greatly reduced, allowing for shorter release cycles and quicker feedback from customers and users. Still, with all of these tools and methods, how can teams stay on top of what is taking place across their infrastructure and codebase? Hopping between services a...
Virtualization over the past years has become a key strategy for IT to acquire multi-tenancy, increase utilization, develop elasticity and improve security. And virtual machines (VMs) are quickly becoming a main vehicle for developing and deploying applications. The introduction of containers seems to be bringing another and perhaps overlapped solution for achieving the same above-mentioned benefits. Are a container and a virtual machine fundamentally the same or different? And how? Is one techn...
SYS-CON Events announced today that MobiDev, a client-oriented software development company, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place June 6-8, 2017, at the Javits Center in New York City, NY, and the 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. MobiDev is a software company that develops and delivers turn-key mobile apps, websites, web services, and complex softw...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm.
What sort of WebRTC based applications can we expect to see over the next year and beyond? One way to predict development trends is to see what sorts of applications startups are building. In his session at @ThingsExpo, Arin Sime, founder of WebRTC.ventures, will discuss the current and likely future trends in WebRTC application development based on real requests for custom applications from real customers, as well as other public sources of information,
Interoute has announced the integration of its Global Cloud Infrastructure platform with Rancher Labs’ container management platform, Rancher. This approach enables enterprises to accelerate their digital transformation and infrastructure investments. Matthew Finnie, Interoute CTO commented “Enterprises developing and building apps in the cloud and those on a path to Digital Transformation need Digital ICT Infrastructure that allows them to build, test and deploy faster than ever before. The int...
Whether you like it or not, DevOps is on track for a remarkable alliance with security. The SEC didn’t approve the merger. And your boss hasn’t heard anything about it. Yet, this unruly triumvirate will soon dominate and deliver DevSecOps faster, cheaper, better, and on an unprecedented scale. In his session at DevOps Summit, Frank Bunger, VP of Customer Success at ScriptRock, discussed how this cathartic moment will propel the DevOps movement from such stuff as dreams are made on to a practic...
ChatOps is an emerging topic that has led to the wide availability of integrations between group chat and various other tools/platforms. Currently, HipChat is an extremely powerful collaboration platform due to the various ChatOps integrations that are available. However, DevOps automation can involve orchestration and complex workflows. In his session at @DevOpsSummit at 20th Cloud Expo, Himanshu Chhetri, CTO at Addteq, will cover practical examples and use cases such as self-provisioning infra...
The cloud competition for database hosts is fierce. How do you evaluate a cloud provider for your database platform? In his session at 18th Cloud Expo, Chris Presley, a Solutions Architect at Pythian, gave users a checklist of considerations when choosing a provider. Chris Presley is a Solutions Architect at Pythian. He loves order – making him a premier Microsoft SQL Server expert. Not only has he programmed and administered SQL Server, but he has also shared his expertise and passion with budd...
"My role is working with customers, helping them go through this digital transformation. I spend a lot of time talking to banks, big industries, manufacturers working through how they are integrating and transforming their IT platforms and moving them forward," explained William Morrish, General Manager Product Sales at Interoute, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Apache Hadoop is emerging as a distributed platform for handling large and fast incoming streams of data. Predictive maintenance, supply chain optimization, and Internet-of-Things analysis are examples where Hadoop provides the scalable storage, processing, and analytics platform to gain meaningful insights from granular data that is typically only valuable from a large-scale, aggregate view. One architecture useful for capturing and analyzing streaming data is the Lambda Architecture, represent...
SYS-CON Events announced today that Ocean9will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Ocean9 provides cloud services for Backup, Disaster Recovery (DRaaS) and instant Innovation, and redefines enterprise infrastructure with its cloud native subscription offerings for mission critical SAP workloads.
With billions of sensors deployed worldwide, the amount of machine-generated data will soon exceed what our networks can handle. But consumers and businesses will expect seamless experiences and real-time responsiveness. What does this mean for IoT devices and the infrastructure that supports them? More of the data will need to be handled at - or closer to - the devices themselves.
In his session at DevOps Summit, Tapabrata Pal, Director of Enterprise Architecture at Capital One, will tell a story about how Capital One has embraced Agile and DevOps Security practices across the Enterprise – driven by Enterprise Architecture; bringing in Development, Operations and Information Security organizations together. Capital Ones DevOpsSec practice is based upon three "pillars" – Shift-Left, Automate Everything, Dashboard Everything. Within about three years, from 100% waterfall, C...